PEGylation and its impact on the design of new protein-based medicines

Future Medicinal Chemistry

Volumn 6, Issue 16, 2014, Pages 1829-1846

  Ginn, Claire ^a   Khalili, Hanieh ^a   Lever, Rebecca ^a   Brocchini, Steve ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; MACROGOL DERIVATIVE; PROTEIN;

BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MARKETING; DRUG SAFETY; DRUG SOLUBILITY; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY CLEARANCE; REVIEW; CHEMISTRY; METABOLISM;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 84911920558     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.125     Document Type: Review

References (179)

1. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp. Cell Res. 317(9), 1261-1269 (2011
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7(1), 21-39 (2008
3. Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. MedChemComm 1(5), 319 (2010
4. Bailon P, Won C. PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6(1), 1-16 (2009
5. Jevsevar S, Kunstelj MI, Porekar VG. PEGylation of therapeutic proteins. Biotechnol. J. 5(1), 113-128 (2010
6. Kang J, DeLuca P, Lee K. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs. 14(2), 363-380 (2009
7. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97(10), 4167-4183 (2008
8. Hamidi M, Rafiei P, Azadi A. Designing PEGylated therapeutic molecules: advantages in ADMET properties. Expert Opin. Drug Discov. 3(11), 1293-1307 (2008
9. Veronese F. Peptide and protein PEGylation a review of problems and solutions. Biomaterials 22(5), 405-417 (2001
10. Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J. Pharm. Sci. 99(6), 2557-2575 (2010
11. Payne RW, Murphy BM, Manning MC. Product development issues for PEGylated proteins. Pharm. Dev. Technol. 16(5), 423-440 (2010
12. Marshall S, Lazar G, Chirino A, Desjarlais J. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8(5), 212-221 (2003
13. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21(4), 414-421 (2003
14. Sola RJ, Grievenow K. Glycosylation of therapeutic proteins an effective strategy to optimize efficacy. Biodrugs 24(1), 9-21 (2010
15. Li H, d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr. Opin. Biotech. 20(6), 678-684 (2009
16. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5), 415-416 (2011
17. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830(12), 5526-5534 (2013
18. Andersen J, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metabol. Pharmacokinet. 24(4), 318-332 (2009
19. Kim H, Robinson S, Csaky K. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol. Vis. 15, 2803-2812 (2009
20. Otagiri M, Chuang V. Pharmaceutically important pre-And posttranslational modifications on human serum albumin. Bio. Pharm. Bull. 32(4), 527-534 (2009
21. Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J. Biol. Chem. 284(38), 25612-25619 (2009
22. Tuan Giam Chuang V, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 19(5), 569-577 (2002
23. Dennis M, Zhang M, Meng Y, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277(38), 35035-35043 (2002
24. Sung C, Nardelli B, LaFleur D, et al. An IFN-β-Albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Interferon Cytokine Res. 23(1), 25-36 (2003
25. Halpern W, Riccobene T, Agostini H, et al. Albugranin TM, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res. 19(11), 1720-1729 (2002
26. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, Mchutchison JG. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25(12), 1411-1419 (2007
27. Trussel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug. Chem. 20, 2286-2292 (2009
28. Abuchowski A, Es T, Palczuk N, Davis F. Alteration of immunlogical properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252(11), 3578-3581 (1977
29. Davis F. The orgin of pegnology. Adv. Drug Deliv. Rev. 54, 457-458 (2002
30. Zalipsky S. Chemistry of poly(ethylene glycol) conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16, 157-182 (1995
31. Greenwald R, Choe Y, McGuire J, Conover C. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55, 217-250 (2003
32. Roberts M, Bentley M, Harris J. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476 (2002
33. Harris J, Chess R. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Dis. 2(3), 214-221 (2003
34. Pasut G, Guiotto A, Veronese F. Protein, peptide and nonpeptide drug PEGylation for therapeutic application. Expert Opin. Ther. Pat. 14(5), 1-36 (2004
35. Veronese F, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10(21), 1451-1458 (2005
36. Pasut G, Veronese F. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32, 933-961 (2007
37. Kochendoerfer G. Site-specific polymer modification of therapeutic proteins. Curr. Opin. Chem. Biol. 9, 555-560 (2005
38. Gauthier M, Klok H. Peptide/protein-polymer conjugates: synthetic strategies and design concepts. Chem. Comm. (Camb.) 23, 2591-2611 (2008
39. Lutz J, Borner H. Modern trends in polymer bioconjugates design. Prog. Polym. Sci. 33, 1-39 (2008
40. Heredia K, Maynard M. Synthesis of protein-polymer conjugates. Org. Biomol. Chem. 5(1), 45-53 (2007
41. Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metabol. Dispos. 35(1), 9-16 (2007
42. Caliceti P, Veronese F. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55(10), 1261-1277 (2003
43. Fee C. Size comparison between proteins PEGylated with branched and linear poly (ethylene glycol) molecules. Biotechnol. Bioeng. 98(4), 725-731 (2007
44. Fontana A Spolaore B Mero A, et al The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites. In: PEGylated Protein Drugs: Basic Science and Clinical Applications. Veronese FM (Ed.). Birkhauser, Basel, Switzerland, 89-112 (2009
45. Foster GR Pegylated Interferons for the Treatment of Chronic Hepatitis C: Pharmacological and Clinical Differences between peginterferon-2a and peginterferon-2b. Drugs 70(2), 147-165 (2010
46. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 34, 975-982 (2002
47. Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin. Emerg. Drugs 15(4), 535-544 (2010
48. Munir S, Saleem S, Idrees M, et al. Hepatitis C treatment: current and future perspectives. Virol. J. 7(1), 296-301 (2010
49. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin. Biol. Ther. 11 (3), 301-313 (2011
50. Petta S, Craxi A. Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. Liver Int. 31, 36-44 (2011
51. Rajan RS, Li T, Aras M, et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 15(5), 1063-1075 (2006
52. Hadziyannis S. Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004
53. Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43, 943-953 (2006
54. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in subsets of older and younger HCV genotype 1 patients. J. Viral Hepat. 16(10), 724-731 (2009
55. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-Alpha2b. J. Interferon Cytokine Res. 21(12), 1103-1115 (2001
56. Lee K, Moon S, Park M, et al. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 16(6), 813-818 (1999
57. Zhang C, Hekmatfar S, Ramanathan A, Karuri NW. PEGylated human plasma fibronectin is proteolytically stable, supports cell adhesion, cell migration, focal adhesion assembly, and fibronectin fibrillogenesis. Biotechnol. Prog. 29(2), 493-504 (2013
58. Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl Acad. Sci. USA 88(16), 7185-7189 (1991
59. Mancini S, Amorotti E, Vecchio S, Ponz De Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg. Med. 5(3), 193-200 (2010
60. Giezen T, Mantel-Teeuwisse A, Straus S, Schellekens H, Leufkens H, Egberts A. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300(16), 1887-1896 (2008
61. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 100(2), 354-387 (2011
62. Fuertges F, Abuchowski A. The clinical efficacy of poly(ethylene glycol) modified proteins. J. Cont. Rel. 11, 139-148 (1990
63. Wang Y, Youngster S, Grace M, Bausch J, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54, 547-570 (2002
64. Pasut G, Sergi M, Veronese F. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv. Drug Deliv. Rev. 60, 69-78 (2008
65. Piedmonte D, Treuheit M. Formulation of Neulasta (pegfilgrastim). Adv. Drug Deliv. Rev. 60, 50-58 (2008
66. Sherman M, Saifer M, Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv. Drug Deliv. Rev. 60, 59-68 (2008
67. Young M, Malavalli A, Winslow N, Candegriff K, Winslow R. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transl. Res. 149(6), 333-342 (2007
68. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42(2), 152-157 (1998
69. Sandborn W, Feagan B, Stoinov S, et al. Certolizumab Pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007
70. CimziaR, package insert. UCB, London, UK (2008
71. Parkinson C, Scarlett J, Trainer P. Pegvisomant in the treatment of acromegaly. Adv. Drug Deliv. Rev. 55(10), 1303-1314 (2003
72. Yin D, Vreeland F, Schaaf L, Millham R, Duncan B, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonish Pegvisomant: implications for cancer therapy. Clin. Cancer Res. 13(3), 1000-1009 (2007
73. Kubetzko S, Sarkar C, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68, 1439-1454 (2005
74. Veronese F, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10(21), 1451-1458 (2005
75. Pasut G, Guiotto A, Veronese F. Protein, peptide and nonpeptide drug PEGylation for therapeutic application. Expert Opin. Ther. Pat. 14(5), 1-36 (2004
76. Dust JM, Fang ZH, Harris JM. Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules 23(16), 3742-3746 (1990
77. Kusterle M, Jevševar S, Porekar VG. Size of pegylated protein conjugates studied by various methods. Acta Chem. Slov. 55, 594-601 (2008
78. Veronese FM, Caliceti P, Schiavon O. Branched and linear Poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioact. Compat. Polym. 12, 196-207 (1997
79. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjug. Chem. 6(1), 62-69 (1995
80. Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug. Chem. 15(6), 1304-1313 (2004
81. Foster GR Pegylated Interferons for the Treatment of Chronic Hepatitis C: Pharmacological and Clinical Differences between peginterferon-2a and peginterferon-2b. Drugs 70(2), 147-165 (2010
82. Kinstler O, Brems D, Lauren S, Paige A, Hamburger J, Treuheit M. Characterization and stability of N-Terminally PEGylated rhG-CSF. Pharm. Res. 13(7), 996-1002 (1996
83. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-Terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54(4), 477-485 (2002
84. Bell S, Fam C, Chlipala E, et al. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-α protein therapeutic. Bioconjug. Chem. 19(1), 299-305 (2008
85. Wang J, Hu T, Liu Y, Zhang G, Ma G, Su Z. Kinetic and stoichiometric analysis of the modification process for N-Terminal PEGylation of staphylokinase. Anal. Biochem. 412(1), 114-116 (2011
86. Lee H, Jang IH, Ryu SH, Park TG. N-Terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20(5), 818-825 (2003
87. Tong Y, Zhong K, Tian H, et al. Characterization of a monoPEG20000-Endostar. Int. J. Biol. Macromol. 46(3), 331-336 (2010
88. Na DH, Lee KC, Deluca PP. PEGylation of octreotide: II. Effect of N-Terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm. Res. 22(5), 743-749 (2005
89. Cindric M, Cepo T, Galic N, et al. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J. Pharmaceut. Biomed. 44(2), 388-395 (2007
90. Nie Y, Zhang X, Wang X, Chen J. Preparation and stability of N-Terminal mono-PEGylated recombinant human endostatin. Bioconjug. Chem. 17(4), 995-999 (2006
91. Zhai Y, Zhao Y, Lei J, Su Z, Ma G. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. J. Biotechnol. 14, 259-266 (2009
92. Hershfield M, Chaffee S. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl Acad. Sci. USA. 88(16), 7185-7189 (1991
93. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-Alpha with full bioactivity. Nat. Biotechnol. 21, 546-552 (2003
94. EMEA. Cimzia 'assesment report'. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/001037/WC500069735.pdf
95. Gadgil HS, Bondarenko PV, Pipes GD, et al. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal. Biochem. 355(2), 165-174 (2006
96. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161(2), 461-472 (2012
97. Bloom L, Calabro V. FN3: a new protein scaffold reaches the clinic. Drug Discov. Today 14, 949-955 (2009
98. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel. 24(1-2), 3-9 (2011
99. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476 (2002
100. Alley S, Benjamin D, Jeffrey S, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19, 759-765 (2008
101. Baldwin AD, Kiick KL. Tunable degradation of maleimide-Thiol adducts in reducing environments. Bioconjug. Chem. 22(10), 1946-1953 (2011
102. Baldwin AD, Kiick KL. Reversible maleimide-Thiol adducts yield glutathione-sensitive poly(ethylene glycol)-heparin hydrogels. Polym. Chem. 4(1), 133 (2012
103. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30(2), 184-189 (2012
104. Toda N, Asano S, Barbas CF 3rd. Rapid, stable, chemoselective labeling of thiols with Julia-Kocienski-like reagents: a serumstable alternative to maleimide-based protein conjugation. Angew Chem. Int. Ed. Engl. 52(48), 12592-12596 (2013
105. Lyon R, Setter JR, Bovee TD, et al. Self-stabilizing ADCs: antibody-drug conjugates prepared with maleimido druglinkers that catalyze their own thiosuccinimide ring hydrolysis. Presented at: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA (2013). (Abstract 4333
106. Badescu G, Bryant P, Swierkosz J, et al. A new reagent for stable thiol-specific conjugation. Bioconjug. Chem. 25(3), 460-469 (2013
107. Balan S, Choi J, Godwin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug. Chem. 18(1), 61-76 (2007
108. Shaunak S, Godwin A, Choi J, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat. Chem. Bio. 2 (6), 312-313 (2006
109. Schumacher FF, Nobles M, Ryan CP, et al. In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug. Chem. 1-5 (2011
110. Godwin AR, Brocchini SJ. Conjugated proteins and peptides. WO2010100430A1 (2012
111. Brocchini S, Bryant P, Cong Y, Choi J, Godwin A, Powell K. Novel conjugated proteins and peptides. WO2009047500 (2009
112. Woestenenk E, Hammarstrom M, van den Berg S, Hard T, Berglund H. His tag effect on solubility of human proteins produced in Escherichia coli: a comparison between four expression vectors. J. Struct. Func. Genomics 5(3), 217-229 (2004
113. Li M, Huang D. On-column refolding purification and characterization of recombinant human interferon-?1 produced in Escherichia coli. Protein Expr. Purif. 53(1), 119-123 (2007
114. Gaberc-Porekar V, Menart V. Potential for using histidine tags in purification of proteins at large scale. Chem. Eng. Technol. 28(11), 1306-1314 (2005
115. Mayer A, Francis RJ, Sharma SK, et al. A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin. Cancer Res. 12(21), 6509-6516 (2006
116. Tolner B, Smith L, Hillyer T, et al. From laboratory to Phase I/II cancer trials with recombinant biotherapeutics. Eur. J. Cancer 43(17), 2515-2522 (2007
117. Murphy R, Green S, Ritter G, et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep. Biochem. Biotech. 35(2), 119-134 (2005
118. Kaslow D, Shiloach J. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Nat. Biotechnol. 12(5), 494-499 (1994
119. Gauthier MA, Klok HA. Arginine-specific modification of proteins with polyethylene glycol. Biomacromolecules 12, 482-493 (2010
120. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54, 487-504 (2002
121. Maullu C, Raimondo D, Caboi F, et al. Site-directed enzymatic PEGylation of the human granulocyte colonystimulating factor. FEBS J. 276(22), 6741-6750 (2009
122. Rabuka D. Chemoenzymatic methods for site-specific protein modification. Curr. Opin. Chem. Biol. 14, 790-796 (2010
123. Defrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16(9), 833-843 (2006
124. Plesner B, Westh P, Nielsen A. Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa. Int. J. Pharm. 406, 62-68 (2011
125. Stennicke HR, Ostergaard H, Bayer RJ, et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Tierärztliche Praxis Grobtiere 36(3), 163-169 (2008
126. Henderson GE, Isett KD, Gerngross TU. Site-specific modification of recombinant proteins: a novel platform for modifying glycoproteins expressed in E. coli. Bioconjug. Chem. 22(5), 903-912 (2011
127. Jones MW, Mantovani G, Blindauer CA, et al. Direct peptide bioconjugation/PEGylation at tyrosine with linear and branched polymeric diazonium salts. J. Am. Chem. Soc. 134(17), 7406-7413 (2012
128. Schlick TL, Ding Z, Kovacs EW, Francis MB. Dual-surface modification of the tobacco mosaic virus. J. Am. Chem. Soc. 127(11), 3718-3723 (2005
129. Gault VA, Kerr BD, Irwin N, Flatt PR. C-Terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem. Pharmacol. 75(12), 2325-2333 (2008
130. Rajan RS, Li T, Aras M, et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 15(5), 1063-1075 (2006
131. Basu A, Yang K, Wang M, et al. Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem. 17(3), 618-630 (2006
132. Gaertner HF, Offord RE. Site-specific attachment of functionalized poly (ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 7(1), 38-44 (1996
133. Gilmore JM, Scheck RA, Esser-Kahn AP, Joshi NS, Francis MB. N-Terminal protein modification through a biomimetic transamination reaction. Angew Chem. Int. Ed. 45(32), 5307-5311 (2006
134. Lee B, Kwon J, Kim H, Yamamoto S. Solid-phase PEGylation of recombinant interferon α-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem. 18(6), 1728-1734 (2007
135. Thom J, Anderson D, McGregor J, Cotton G. Recombinant protein hydrazides: application to site-specific protein PEGylation. Bioconjug. Chem. 22(6), 1017-1020 (2011
136. Toda N, Asano S, Barbas CF. Rapid, stable, chemoselective labeling of thiols with julia-kocienski-like reagents: a serumstable alternative to maleimide-based protein conjugation. Angew. Chem. Int. Ed. Engl. 52(48), 12592-12596 (2013
137. Brocchini S, Godwin A, Balan S, Choi JW, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv. Drug Deliv. Rev. 60(1), 3-12 (2008
138. Balan S, Choi JW, Godwin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug. Chem. 18(1), 61-76 (2007
139. Khalili H, Godwin A, Choi J, Lever R, Brocchini S. Comparative binding of disulfide-bridged PEG-Fabs. Bioconjug. Chem. 23(11), 2262-2277 (2012
140. Jones MW, Strickland RA, Schumacher FF, et al. Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. J. Am. Chem. Soc. 134(3), 1847-1852 (2011
141. Mero A, Spolaore B, Veronese FM, Fontana A. Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. Bioconjug. Chem. 20(2), 384-389 (2009
142. Cong Y, Pawlisz E, Bryant P, et al. Site-specific PEGylation at histidine tags. Bioconjug. Chem. 23(2), 248-263 (2012
143. Deiters A, Cropp T, Summerer D, Mukherji M, Schultz P. Site-specific PEGylation of proteins containing unnatural amino acids. Bioorg. Med. Chem. Lett. 14(23), 5743-5745 (2004
144. Carrico IS. Chemoselective modification of proteins: hitting the target. Chem. Soc. Rev. 37(7), 1423-1431 (2008
145. Broyer RM, Grover GN, Maynard HD. Emerging synthetic approaches for protein-polymer conjugations. Chem. Comm. 47, 2212-2226 (2011
146. Ban H, Gavrilyuk J, Barbas III CF. Tyrosine bioconjugation through aqueous ene-Type reactions: a click-like reaction for tyrosine. J. Am. Chem. Soc. 132(5), 1523-1525 (2010
147. Minamihata K, Goto M, Kamiya N. Site-specific protein cross-linking by peroxidase-catalyzed activation of a tyrosine-containing peptide tag. Bioconjug. Chem. 22, 74-81 (2011
148. Joralemon MJ, McRae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-Assembled systems. Chem. Commun. (Camb.) 46(9), 1377 (2010
149. Johnson JA, Lu YY, Van Deventer JA, Tirrell DA. Residuespecific incorporation of non-canonical amino acids into proteins: recent developments and applications. Curr. Opin. Chem. Biol. 14, 774-780 (2010
150. Liu CC, Schultz PG. Adding new chemistries to the genetic code. Ann. Rev. Biochem. 79, 413-444 (2010
151. Voloshchuk N, Montclare JK. Incorporation of unnatural amino acids for synthetic biology. Mol. Biosyst. 6(1), 65-80 (2009
152. Connor RE, Tirrell DA. Non-canonical amino acids in protein polymer design. Polym. Rev. 47(1), 9-28 (2007
153. Wang A, Winblade Nairn N, Johnson RS, Tirrell DA, Grabstein K. Processing of N-Terminal unnatural amino acids in recombinant human interferon-β in Escherichia coli. Chembiochem 9(2), 324-330 (2008
154. Liao J. Protein and cellular engineering with unnatural amino acids. Biotechnol. Prog. 23(1), 28-31 (2007
155. Van Hest J. Biosynthetic-synthetic polymer conjugates. Polym. Rev. 47(1), 63-92 (2007
156. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16(10), 761-770 (2003
157. Rosendahl M, Doherty D, Smith S, Carlson S, Chlipala E, Cox G. A long-Acting, highly potent interferon a-2 conjugate created using site-specific PEGylation. Bioconjug. Chem. 16, 200-207 (2005
158. Mei B, Pan C, Jiang H, et al. Rational design of a fully active, long-Acting PEGylated factor VIII for hemophilia A treatment. Blood 116(2), 270-279 (2010
159. Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjug. Chem. 16(5), 1291-1298 (2005
160. Filipovska A, Rackham O. Building a parallel metabolism within the cell. ACS Chem. Biol. 3(1), 51-63 (2008
161. Ostergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118(8), 2333-2341 (2011
162. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83(4), 601-606 (1994
163. Garay RP, Labaune JP. Immunogenicity of polyethylene glycol (PEG). Open Conf. Proc. J. 2, 104-107 (2011
164. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEGasparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110(1), 103-111 (2007
165. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a Phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8(1), R12 (2006
166. Romberg B, Metselaar JM, Baranyi L, et al. Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Int. J. Pharm. 331(2), 186-189 (2007
167. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 519, 81-99 (2003
168. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 3(6), 623-630 (2008
169. Boddy AV, Plummer ER, Todd R, et al. A Phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 11(21), 7834-7840 (2005
170. Homsi J, Simon GR, Garrett CR, et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 13(19), 5855-5861 (2007
171. Constantinou A, Epenetos AA, Hreczuk-Hirst D, et al. Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug. Chem. 20(5), 924-931 (2009
172. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300(1-2), 125-130 (2005
173. Konieczny S, Fik CP, Averesch NJ, Tiller JC. Organosoluble enzyme conjugates with poly(2-oxazoline) s via pyromellitic acid dianhydride. J. Biotechnol. 159(3), 195-203 (2012
174. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-Acting, acylated analog of human insulin. Pharm. Res. 21(8), 1498-1504 (2004
175. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J. Pharm. Sci. 85(3), 304-308 (1996
176. Seymour LW, Flanagan PA, al-Shamkhani A, et al. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-Targeted drug delivery. Sel. Cancer Ther. 7(2), 59-73 (1991
177. Ulbrich K, Subr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv. Drug Deliv. Rev. 62(2), 150-166 (2010
178. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester H, Skerra A. Fusion of a recombinant antibody fragment with a homo-Amino-Acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng. Des. Sel. 20(6), 273 (2007
179. Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27(12), 1186-1190 (2009